A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: Results of a randomised, controlled, dose-escalation phase 1 trial

Vaccine

Volumn 30, Issue 43, 2012, Pages 6163-6174

  Richmond, P C ^a   Nissen, M D ^b,c   Marshall, H S ^d   Lambert, S B ^b,c   Roberton, D ^d   Gruber, W C ^e   Jones, T R ^e   Arora, A ^e,f  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e PFIZER INC   (United States)

^f NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

Bacterial outer membrane proteins; Bactericidal antibodies, Factor H binding protein; Meningococcal vaccines; Neisseria meningitidis serogroup B

Indexed keywords

BACTERIAL VACCINE; BIVALENT RECOMBINANT LIPIDATED FACTOR H BINDING PROTEIN; COMPLEMENT; IMMUNOGLOBULIN G ANTIBODY; NEISSERIA MENINGITIDIS VACCINE; PLACEBO; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADULT; AMINO ACID SEQUENCE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; BACTERIAL STRAIN; CHILL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCEMIA; MENINGOCOCCOSIS; MULTICENTER STUDY; MYALGIA; NAUSEA; NEISSERIA MENINGITIDIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SERUM BACTERICIDAL ACTIVITY; SIDE EFFECT; TONSILLITIS; TOOTH DISEASE; URTICARIA; VACCINATION REACTION; VOMITING;

ADULT; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; COMPLEMENT SYSTEM PROTEINS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; SERUM BACTERICIDAL ANTIBODY ASSAY; VACCINES, SYNTHETIC; YOUNG ADULT;

EID: 84865789748     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.07.065     Document Type: Article

References (53)

1. Harrison L.H., Trotter C.L., Ramsay M.E. Global epidemiology of meningococcal disease. Vaccine 2009, 27(Suppl. 2):B51-B63.
2. Girard M.P., Preziosi M.P., Aguado M.T., Kieny M.P. A review of vaccine research and development: meningococcal disease. Vaccine 2006, 24(22):4692-4700.
3. Pace D., Pollard A.J., Meningococcal A.C.Y. W-135 polysaccharide-protein conjugate vaccines. Arch Dis Child 2007, 92(10):909-915.
4. Bruge J., Bouveret-Le Cam N., Danve B., Rougon G., Schulz D. Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers. Vaccine 2004, 22(9-10):1087-1096.
5. Wyle F.A., Artenstein M.S., Brandt B.L., Tramont E.C., Kasper D.L., Altieri P.L., et al. Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis 1972, 126(5):514-521.
6. Finne J., Leinonen M., Makela P.H. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983, 2(8346):355-357.
7. Annual report of the Australian Meningococcal Surveillance Programme, 2009. Commun Dis Intell 2010, 34(3):291-302.
8. Cohn A.C., MacNeil J.R., Harrison L.H., Hatcher C., Theodore J., Schmidt M., et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010, 50(2):184-191.
9. Racloz V.N., Luiz S.J. The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology. BMC Infect Dis 2010, 10:175.
10. United Kingdom Health Protection Agency. Meningococcal Reference Unit: Isolates of Neisseria menengitidis; England and Wales, by serogroup & calendar year, 1998-2010*.; [accessed March 2012]. http://www.hpa.org.uk/web/HPAweb%26HPAwebStandard/HPAweb_C/1234859712887.
11. Jelfs J., Munro R., Wedege E., Caugant D.A. Sequence variation in the porA gene of a clone of Neisseria meningitidis during epidemic spread. Clin Diagn Lab Immunol 2000, 7(3):390-395.
12. Tondella M.L., Popovic T., Rosenstein N.E., Lake D.B., Carlone G.M., Mayer L.W., et al. Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team. J Clin Microbiol 2000, 38(9):3323-3328.
13. Fletcher L.D., Bernfield L., Barniak V., Farley J.E., Howell A., Knauf M., et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 2004, 72(4):2088-2100.
14. Masignani V., Comanducci M., Giuliani M.M., Bambini S., Adu-Bobie J., Arico B., et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 2003, 197(6):789-799.
15. Zhu D., Zhang Y., Barniak V., Bernfield L., Howell A., Zlotnick G. Evaluation of recombinant lipidated P2086 protein as a vaccine candidate for group B Neisseria meningitidis in a murine nasal challenge model. Infect Immun 2005, 73(10):6838-6845.
16. Madico G., Welsch J.A., Lewis L.A., McNaughton A., Perlman D.H., Costello C.E., et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 2006, 177(1):501-510.
17. Schneider M.C., Exley R.M., Chan H., Feavers I., Kang Y.H., Sim R.B., et al. Functional significance of factor H binding to Neisseria meningitidis. J Immunol 2006, 176(12):7566-7575.
18. Schneider M.C., Prosser B.E., Caesar J.J., Kugelberg E., Li S., Zhang Q., et al. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature 2009, 458(7240):890-893.
19. Jiang H.Q., Hoiseth S.K., Harris S.L., McNeil L.K., Zhu D., Tan C., et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 2010, 28(37):6086-6093.
20. Lucidarme J., Tan L., Exley R.M., Findlow J., Borrow R., Tang C.M. Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein. Clin Vaccine Immunol 2011, 18(6):1002-1014.
21. Murphy E., Andrew L., Lee K.L., Dilts D.A., Nunez L., Fink P.S., et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 2009, 200(3):379-389.
22. Pajon R., Beernink P.T., Harrison L.H., Granoff D.M. Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine 2010, 28(9):2122-2129.
23. Anderson A.S., Jansen K.U., Eiden J. New frontiers in meningococcal vaccines. Expert Rev Vaccines 2011, 10(5):617-634.
24. Bai X., Findlow J., Borrow R. Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin Biol Ther 2011, 11(7):969-985.
25. Panatto D., Amicizia D., Lai P.L., Gasparini R. Neisseria meningitidis B vaccines. Expert Rev Vaccines 2011, 10(9):1337-1351.
26. European Medicines Agency Notes for Guidance on Preclinical Pharmacologoical and Toxicological Testing of Vaccines 1997, European Agency for the Evaluation of Medicinal Products, London.
27. United States Food and Drug Administration. Guidance for Industry, toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. Draft Guidance: US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, 2005.
28. McNeil L.K., Murphy E., Zhao X.J., Guttmann S., Harris S.L., Scott A.A., et al. Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. Vaccine 2009, 27(25-26):3417-3421.
29. Ala'aldeen D.A., Flint M., Oldfield N.J., Omer S.A., McNeil L.K., Jiang Q., et al. Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage. Vaccine 2010, 28(48):7667-7675.
30. Farrington P., Miller E. Meningococcal vaccine trials. Methods Mol Med 2001, 66:371-393.
31. Borrow R., Balmer P., Miller E. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine 2005, 23(17-18):2222-2227.
32. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969, 129(6):1307-1326.
33. Gotschlich E.C., Goldschneider I., Artenstein M.S. Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J Exp Med 1969, 129(6):1367-1384.
34. World Health Organization. Requirements for meningococcal polysaccharide vaccine. World Health Organiztion technical report series. Geneva, Switzerland. 1976.
35. Boslego J., Garcia J., Cruz C., Zollinger W., Brandt B., Ruiz S., et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine 1995, 13(9):821-829.
36. Holst J., Feiring B., Fuglesang J.E., Hoiby E.A., Nokleby H., Aaberge I.S., et al. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine 2003, 21(7-8):734-737.
37. Milagres L.G., Ramos S.R., Sacchi C.T., Melles C.E., Vieira V.S., Sato H., et al. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect Immun 1994, 62(10):4419-4424.
38. Perkins B.A., Jonsdottir K., Briem H., Griffiths E., Plikaytis B.D., Hoiby E.A., et al. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J Infect Dis 1998, 177(3):683-691.
39. Sierra G.V., Campa H.C., Varcacel N.M., Garcia I.L., Izquierdo P.L., Sotolongo P.F., et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 1991, 14(2):195-207. discussion 08-10.
40. Wong S., Lennon D., Jackson C., Stewart J., Reid S., Crengle S., et al. New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months. Pediatr Infect Dis J 2007, 26(4):345-350.
41. Borrow R., Carlone G.M., Rosenstein N., Blake M., Feavers I., Martin D., et al. Neisseria meningitidis group B correlates of protection and assay standardization-international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine 2006, 24(24):5093-5107.
42. Fischer M., Carlone G.M., Holst J., Williams D., Stephens D.S., Perkins B.A. Neisseria meningitidis serogroup B outer membrane vesicle vaccine in adults with occupational risk for meningococcal disease. Vaccine 1999, 17(19):2377-2383.
43. Oster P., Lennon D., O'Hallahan J., Mulholland K., Reid S., Martin D. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 2005, 23(17-18):2191-2196.
44. Thornton V., Lennon D., Rasanathan K., O'Hallahan J., Oster P., Stewart J., et al. Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control. Vaccine 2006, 24(9):1395-1400.
45. Holst J., Martin D., Arnold R., Huergo C.C., Oster P., O'Hallahan J., et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 2009, 27(Suppl 2):B3-B12.
46. Findlow J., Borrow R., Snape M.D., Dawson T., Holland A., John T.M., et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 2010, 51(10):1127-1137.
47. Gossger N., Snape M.D., Yu L.M., Finn A., Bona G., Esposito S., et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012, 307(6):573-582.
48. Santolaya M.E., O'Ryan M.L., Valenzuela M.T., Prado V., Vergara R., Munoz A., et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012, 379(9816):617-624.
49. Toneatto D., Ismaili S., Ypma E., Vienken K., Oster P., Dull P. The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans. Hum Vaccin 2011, 7(6):646-653.
50. Keiser P.B., Biggs-Cicatelli S., Moran E.E., Schmiel D.H., Pinto V.B., Burden R.E., et al. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine 2011, 29(7):1413-1420.
51. Keiser P.B., Biggs-Cicatelli S., Moran E.E., Schmiel D.H., Pinto V.B., Burden R.E., et al. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine 2011, 29(7):1413-1420.
52. Marshall H.S., Richmond P.C., Nissen M.D., Jiang Q., Anderson A.S., Jansen K.U., et al. Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18 to 36 months: a phase 1 randomized controlled clinical trial. Pediatr Infect Dis J 2012, Available at:, [last accessed 11.07.2012]. http://journals.lww.com/pidj/Abstract/publishahead/Safety_and_Immunogenicity_of_a_Meningococcal_B.98647.aspx, 10.1097/INF.0b013e31826327e4.
53. Richmond P.C., Marshall H.S., Nissen M.D., Jiang Q., Jansen K.U., Garces-Sanchez M., et al. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012, 12(8):597-607.